Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Butylglyceryl Pectin Nanoparticles: Synthesis, Formulation and Characterization.

Bostanudin MF, Arafat M, Sarfraz M, Górecki DC, Barbu E.

Polymers (Basel). 2019 May 2;11(5). pii: E789. doi: 10.3390/polym11050789.

2.

P2X7 purinoceptor as a therapeutic target in muscular dystrophies.

Górecki DC.

Curr Opin Pharmacol. 2019 Aug;47:40-45. doi: 10.1016/j.coph.2019.02.003. Epub 2019 Mar 20. Review.

PMID:
30901735
3.

Dystrophic mdx mouse myoblasts exhibit elevated ATP/UTP-evoked metabotropic purinergic responses and alterations in calcium signalling.

Róg J, Oksiejuk A, Gosselin MRF, Brutkowski W, Dymkowska D, Nowak N, Robson S, Górecki DC, Zabłocki K.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1138-1151. doi: 10.1016/j.bbadis.2019.01.002. Epub 2019 Jan 24.

PMID:
30684640
4.

P2RX7 Purinoceptor as a Therapeutic Target-The Second Coming?

Young CNJ, Górecki DC.

Front Chem. 2018 Jun 28;6:248. doi: 10.3389/fchem.2018.00248. eCollection 2018. Review.

5.

Proteomics analysis reveals a potential new target protein for the lipid-lowering effect of Berberine8998.

Yu CY, Liu GY, Liu XH, Gui YZ, Liu HM, Zheng HC, Gorecki DC, Patel AV, Yu C, Wang YP.

Acta Pharmacol Sin. 2018 Sep;39(9):1473-1482. doi: 10.1038/aps.2017.200. Epub 2018 Apr 12.

6.

Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.

Al-Khalidi R, Panicucci C, Cox P, Chira N, Róg J, Young CNJ, McGeehan RE, Ambati K, Ambati J, Zabłocki K, Gazzerro E, Arkle S, Bruno C, Górecki DC.

Acta Neuropathol Commun. 2018 Apr 11;6(1):27. doi: 10.1186/s40478-018-0530-4.

7.

Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition.

Young CNJ, Chira N, Róg J, Al-Khalidi R, Benard M, Galas L, Chan P, Vaudry D, Zablocki K, Górecki DC.

J Mol Cell Biol. 2018 Jun 1;10(3):229-242. doi: 10.1093/jmcb/mjx030.

PMID:
28992079
8.

Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles.

Sharma D, Al-Khalidi R, Edgar S, An Q, Wang Y, Young C, Nowis D, Gorecki DC.

Gene Ther. 2017 Feb;24(2):113-119. doi: 10.1038/gt.2016.82. Epub 2016 Dec 22.

PMID:
28004656
9.

Impact of P2RX7 ablation on the morphological, mechanical and tissue properties of bones in a murine model of duchenne muscular dystrophy.

Mohamad NS, Sinadinos A, Górecki DC, Zioupos P, Tong J.

J Biomech. 2016 Oct 3;49(14):3444-3451. doi: 10.1016/j.jbiomech.2016.09.016. Epub 2016 Sep 15.

PMID:
27663621
10.

Dystrophin: The dead calm of a dogma.

Górecki DC.

Rare Dis. 2016 Feb 18;4(1):e1153777. doi: 10.1080/21675511.2016.1153777. eCollection 2016.

11.

P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.

Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, Lefebvre A, Shugay M, Tong J, Vaudry D, Arkle S, doRego JC, Górecki DC.

PLoS Med. 2015 Oct 13;12(10):e1001888. doi: 10.1371/journal.pmed.1001888. eCollection 2015 Oct.

12.

Nanoparticles of alkylglyceryl-dextran-graft-poly(lactic acid) for drug delivery to the brain: Preparation and in vitro investigation.

Toman P, Lien CF, Ahmad Z, Dietrich S, Smith JR, An Q, Molnár É, Pilkington GJ, Górecki DC, Tsibouklis J, Barbu E.

Acta Biomater. 2015 Sep;23:250-262. doi: 10.1016/j.actbio.2015.05.009. Epub 2015 May 15.

PMID:
25983313
13.

A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.

Young CN, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, Gorecki DC.

Autophagy. 2015;11(1):113-30. doi: 10.4161/15548627.2014.994402.

14.

Store-operated calcium entry contributes to abnormal Ca²⁺ signalling in dystrophic mdx mouse myoblasts.

Onopiuk M, Brutkowski W, Young C, Krasowska E, Róg J, Ritso M, Wojciechowska S, Arkle S, Zabłocki K, Górecki DC.

Arch Biochem Biophys. 2015 Mar 1;569:1-9. doi: 10.1016/j.abb.2015.01.025. Epub 2015 Feb 4.

PMID:
25659883
15.

Aberrant location of inhibitory synaptic marker proteins in the hippocampus of dystrophin-deficient mice: implications for cognitive impairment in duchenne muscular dystrophy.

Krasowska E, Zabłocki K, Górecki DC, Swinny JD.

PLoS One. 2014 Sep 26;9(9):e108364. doi: 10.1371/journal.pone.0108364. eCollection 2014.

16.

Purinergic receptors in skeletal muscles in health and in muscular dystrophy.

Krasowska E, Róg J, Sinadinos A, Young CN, Górecki DC, Zabłocki K.

Postepy Biochem. 2014;60(4):483-9. Review.

PMID:
25807827
17.

CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma.

Carter JA, Górecki DC, Mein CA, Ljungberg B, Hafizi S.

Epigenetics. 2013 Jul;8(7):739-47. doi: 10.4161/epi.25075. Epub 2013 May 24.

18.

Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?

Zabłocka B, Goldspink PH, Goldspink G, Górecki DC.

Front Endocrinol (Lausanne). 2012 Nov 1;3:131. doi: 10.3389/fendo.2012.00131. eCollection 2012. No abstract available.

19.

Absence of glial α-dystrobrevin causes abnormalities of the blood-brain barrier and progressive brain edema.

Lien CF, Mohanta SK, Frontczak-Baniewicz M, Swinny JD, Zablocka B, Górecki DC.

J Biol Chem. 2012 Nov 30;287(49):41374-85. doi: 10.1074/jbc.M112.400044. Epub 2012 Oct 5.

20.

Splice variants of the P2X7 receptor reveal differential agonist dependence and functional coupling with pannexin-1.

Xu XJ, Boumechache M, Robinson LE, Marschall V, Gorecki DC, Masin M, Murrell-Lagnado RD.

J Cell Sci. 2012 Aug 15;125(Pt 16):3776-89. doi: 10.1242/jcs.099374. Epub 2012 May 2.

21.

In vitro assessment of alkylglyceryl-functionalized chitosan nanoparticles as permeating vectors for the blood-brain barrier.

Lien CF, Molnár E, Toman P, Tsibouklis J, Pilkington GJ, Górecki DC, Barbu E.

Biomacromolecules. 2012 Apr 9;13(4):1067-73. doi: 10.1021/bm201790s. Epub 2012 Mar 29.

PMID:
22409486
22.

Relationship between the affinity of PEO-PPO-PEO block copolymers for biological membranes and their cellular effects.

Redhead M, Mantovani G, Nawaz S, Carbone P, Gorecki DC, Alexander C, Bosquillon C.

Pharm Res. 2012 Jul;29(7):1908-18. doi: 10.1007/s11095-012-0716-6. Epub 2012 Mar 3.

PMID:
22392332
23.

Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts.

Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC, Murrell-Lagnado R.

Br J Pharmacol. 2012 Feb;165(4):978-93. doi: 10.1111/j.1476-5381.2011.01624.x.

24.

Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma.

Birks SM, Danquah JO, King L, Vlasak R, Gorecki DC, Pilkington GJ.

Neuro Oncol. 2011 Sep;13(9):950-60. doi: 10.1093/neuonc/nor108. Epub 2011 Jul 31.

25.

P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment.

Young CN, Brutkowski W, Lien CF, Arkle S, Lochmüller H, Zabłocki K, Górecki DC.

J Cell Mol Med. 2012 May;16(5):1026-37. doi: 10.1111/j.1582-4934.2011.01397.x.

26.

Simultaneous quantification of Echinacea species, Flos Lonicerae, Radix Scutellaria and Fructus Forsythiae combinations by rapid resolution liquid chromatography.

Ma J, Ma YC, Cai C, Wang D, Hou FF, Luo M, Lu S, Gorecki DC, Patel AV, Chen A, Jin P.

Nat Prod Commun. 2011 May;6(5):639-43.

PMID:
21615024
27.

Simultaneous quantification of Panax and Epimedium species using Rapid Resolution Liquid Chromatography (RRLC).

Ma J, Ma YC, Wang D, Hou FF, Luo M, Lu S, Gorecki DC, Patel AV.

Nat Prod Commun. 2011 May;6(5):581-6.

PMID:
21615012
28.

Knockdown of MLC1 in primary astrocytes causes cell vacuolation: a MLC disease cell model.

Duarri A, Lopez de Heredia M, Capdevila-Nortes X, Ridder MC, Montolio M, López-Hernández T, Boor I, Lien CF, Hagemann T, Messing A, Gorecki DC, Scheper GC, Martínez A, Nunes V, van der Knaap MS, Estévez R.

Neurobiol Dis. 2011 Jul;43(1):228-38. doi: 10.1016/j.nbd.2011.03.015. Epub 2011 Apr 3.

29.

Toward drug delivery into the brain: synthesis, characterization, and preliminary in vitro assessment of alkylglyceryl-functionalized chitosan nanoparticles.

Molnár E, Barbu E, Lien CF, Górecki DC, Tsibouklis J.

Biomacromolecules. 2010 Nov 8;11(11):2880-9. doi: 10.1021/bm100577x. Epub 2010 Oct 4.

PMID:
20919693
30.

Changes in the expression of insulin-like growth factor 1 variants in the postnatal brain development and in neonatal hypoxia-ischaemia.

Beresewicz M, Majewska M, Makarewicz D, Vayro S, Zabłocka B, Górecki DC.

Int J Dev Neurosci. 2010 Feb;28(1):91-7. doi: 10.1016/j.ijdevneu.2009.09.002. Epub 2009 Sep 18.

PMID:
19766709
31.

A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice.

Nicke A, Kuan YH, Masin M, Rettinger J, Marquez-Klaka B, Bender O, Górecki DC, Murrell-Lagnado RD, Soto F.

J Biol Chem. 2009 Sep 18;284(38):25813-22. doi: 10.1074/jbc.M109.033134. Epub 2009 Jun 22.

32.

Mutation in dystrophin-encoding gene affects energy metabolism in mouse myoblasts.

Onopiuk M, Brutkowski W, Wierzbicka K, Wojciechowska S, Szczepanowska J, Fronk J, Lochmüller H, Górecki DC, Zabłocki K.

Biochem Biophys Res Commun. 2009 Aug 28;386(3):463-6. doi: 10.1016/j.bbrc.2009.06.053. Epub 2009 Jun 13.

PMID:
19527684
33.

The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier.

Barbu E, Molnàr E, Tsibouklis J, Górecki DC.

Expert Opin Drug Deliv. 2009 Jun;6(6):553-65. doi: 10.1517/17425240902939143 . Review.

PMID:
19435406
34.

Analysis of assembly and trafficking of native P2X4 and P2X7 receptor complexes in rodent immune cells.

Boumechache M, Masin M, Edwardson JM, Górecki DC, Murrell-Lagnado R.

J Biol Chem. 2009 May 15;284(20):13446-54. doi: 10.1074/jbc.M901255200. Epub 2009 Mar 20.

35.

Aberrant expression of beta-dystroglycan may be due to processing by matrix metalloproteinases-2 and -9 in oral squamous cell carcinoma.

Shang ZJ, Ethunandan M, Górecki DC, Brennan PA.

Oral Oncol. 2008 Dec;44(12):1139-46. doi: 10.1016/j.oraloncology.2008.02.016. Epub 2008 May 19.

PMID:
18487074
36.

Important role of matrix metalloproteinase 9 in epileptogenesis.

Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, Konopka W, Duniec K, Mioduszewska B, Nikolaev E, Walczak A, Owczarek D, Gorecki DC, Zuschratter W, Ottersen OP, Kaczmarek L.

J Cell Biol. 2008 Mar 10;180(5):1021-35. doi: 10.1083/jcb.200708213.

37.

Synaptic alpha-dystrobrevin: localization of a short alpha-dystrobrevin isoform in melanin-concentrating hormone neurons of the hypothalamus.

Hazai D, Lien CF, Hajós F, Halasy K, Górecki DC, Jancsik V.

Brain Res. 2008 Mar 27;1201:52-9. doi: 10.1016/j.brainres.2008.01.046. Epub 2008 Jan 26.

PMID:
18314094
38.

Mechanisms of ATP- and glutamate-mediated calcium signaling in white matter astrocytes.

Hamilton N, Vayro S, Kirchhoff F, Verkhratsky A, Robbins J, Gorecki DC, Butt AM.

Glia. 2008 May;56(7):734-49. doi: 10.1002/glia.20649.

PMID:
18293404
39.

Nuclear-targeted chimeric vector enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo.

Lavigne MD, Yates L, Coxhead P, Górecki DC.

FASEB J. 2008 Jun;22(6):2097-107. doi: 10.1096/fj.07-093765. Epub 2008 Jan 17.

PMID:
18202142
40.

Neuroprotective effects of short peptides derived from the Insulin-like growth factor 1.

Górecki DC, Beresewicz M, Zabłocka B.

Neurochem Int. 2007 Dec;51(8):451-8. Epub 2007 May 16. Review.

PMID:
17582656
41.

Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity.

Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, Gorecki DC, Ottersen OP, Kaczmarek L.

J Biol Chem. 2007 Jun 1;282(22):16036-41. Epub 2007 Apr 10.

42.

Dystrobrevins in muscle and non-muscle tissues.

Rees ML, Lien CF, Górecki DC.

Neuromuscul Disord. 2007 Feb;17(2):123-34. Epub 2007 Jan 23. Review.

PMID:
17251025
43.

"Dressed-up" naked plasmids: emerging vectors for non-viral gene therapy.

Gôrecki DC.

Discov Med. 2006 Oct;6(35):191-7. Review.

44.

Synthesis and characterization of variable-architecture thermosensitive polymers for complexation with DNA.

Pennadam SS, Ellis JS, Lavigne MD, Górecki DC, Davies MC, Alexander C.

Langmuir. 2007 Jan 2;23(1):41-9.

PMID:
17190483
45.

Enhanced gene expression through temperature profile-induced variations in molecular architecture of thermoresponsive polymer vectors.

Lavigne MD, Pennadam SS, Ellis J, Yates LL, Alexander C, Górecki DC.

J Gene Med. 2007 Jan;9(1):44-54.

PMID:
17167816
46.

The nuclear factor-kappaB (NF-kappaB): from a versatile transcription factor to a ubiquitous therapeutic target.

Yates LL, Górecki DC.

Acta Biochim Pol. 2006;53(4):651-62. Epub 2006 Oct 27. Review.

47.

Emerging vectors and targeting methods for nonviral gene therapy.

Lavigne MD, Górecki DC.

Expert Opin Emerg Drugs. 2006 Sep;11(3):541-57. Review.

PMID:
16939390
48.

Expression of alpha-dystrobrevin in blood-tissue barriers: sub-cellular localisation and molecular characterisation in normal and dystrophic mice.

Lien CF, Hazai D, Yeung D, Tan J, Füchtbauer EM, Jancsik V, Górecki DC.

Cell Tissue Res. 2007 Jan;327(1):67-82. Epub 2006 Jul 26.

PMID:
16868787
49.

Changes in immunolocalisation of beta-dystroglycan and specific degradative enzymes in the osteoarthritic synovium.

Wimsey S, Lien CF, Sharma S, Brennan PA, Roach HI, Harper GD, Górecki DC.

Osteoarthritis Cartilage. 2006 Nov;14(11):1181-8. Epub 2006 Jun 8.

50.

Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells.

Yeung D, Zablocki K, Lien CF, Jiang T, Arkle S, Brutkowski W, Brown J, Lochmuller H, Simon J, Barnard EA, Górecki DC.

FASEB J. 2006 Apr;20(6):610-20.

PMID:
16581969

Supplemental Content

Loading ...
Support Center